Design Therapeutics (DSGN) Amortizatization of Intangibles (2020 - 2026)
Design Therapeutics recorded quarterly Amortizatization of Intangibles of $147000.0 in Q1 2026, down 71.29% quarter-over-quarter from $512000.0 in Q4 2025, and down 86.13% year-over-year from $1.1 million in Q1 2025.
Design Therapeutics' Amortizatization of Intangibles history runs 7 years deep, the most recent figure standing at $147000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 86.13% year-over-year to $147000.0; the TTM figure through Mar 2026 stood at $2.3 million (down 57.66% YoY), while the FY2025 annual figure was $3.3 million, down 47.52% from the prior year.
- Amortizatization of Intangibles came in at $147000.0 for Q1 2026 at Design Therapeutics, down from $512000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $6.1 million in Q4 2023 to a low of -$19000.0 in Q1 2022.
- A 5-year average of $1.0 million and a median of $767000.0 in 2025 frame the typical range for Amortizatization of Intangibles.
- Across the five-year window, Amortizatization of Intangibles sank 112.67% in 2022 and surged 18100.0% in 2024, its largest moves.
- Design Therapeutics' Amortizatization of Intangibles stood at $899000.0 in 2022, then soared by 573.64% to $6.1 million in 2023, then slumped by 76.25% to $1.4 million in 2024, then tumbled by 64.39% to $512000.0 in 2025, then tumbled by 71.29% to $147000.0 in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $147000.0, $512000.0, and $767000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Design Therapeutics | 640.15 Mn | 417.32 Mn | - | 147,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 147,000.00 |
| Mar 31, 2026 | 147,000.00 |
| Dec 31, 2025 | 512,000.00 |
| Dec 31, 2025 | 512,000.00 |
| Sep 30, 2025 | 767,000.00 |
| Sep 30, 2025 | 767,000.00 |
| Jun 30, 2025 | 914,000.00 |
| Jun 30, 2025 | 914,000.00 |
| Mar 31, 2025 | 1.06 Mn |
| Mar 31, 2025 | 1.06 Mn |
| Dec 31, 2024 | 1.44 Mn |
| Dec 31, 2024 | 1.44 Mn |
| Sep 30, 2024 | 1.46 Mn |
| Sep 30, 2024 | 1.46 Mn |
| Jun 30, 2024 | 1.57 Mn |
| Jun 30, 2024 | 1.57 Mn |
| Mar 31, 2024 | 1.73 Mn |
| Mar 31, 2024 | 1.73 Mn |
| Dec 31, 2023 | 6.06 Mn |
| Dec 31, 2023 | 6.06 Mn |
| Sep 30, 2023 | 8,000.00 |
| Sep 30, 2023 | 8,000.00 |
| Jun 30, 2023 | 10,000.00 |
| Jun 30, 2023 | 10,000.00 |
| Mar 31, 2023 | 10,000.00 |
| Mar 31, 2023 | 10,000.00 |
| Dec 31, 2022 | 899,000.00 |
| Dec 31, 2022 | 899,000.00 |
| Sep 30, 2022 | 458,000.00 |
| Sep 30, 2022 | 458,000.00 |
| Jun 30, 2022 | 58,000.00 |
| Jun 30, 2022 | 58,000.00 |
| Mar 31, 2022 | -19,000.00 |
| Mar 31, 2022 | -19,000.00 |
| Dec 31, 2021 | -26,000.00 |
| Dec 31, 2021 | -26,000.00 |
| Sep 30, 2021 | -25,000.00 |
| Sep 30, 2021 | -25,000.00 |
| Jun 30, 2021 | -22,000.00 |
| Jun 30, 2021 | -22,000.00 |
| Mar 31, 2021 | 150,000.00 |
| Mar 31, 2021 | 150,000.00 |
| Dec 31, 2020 | 2,000.00 |
| Dec 31, 2020 | 2,000.00 |
| Sep 30, 2020 | 58,000.00 |
| Sep 30, 2020 | 58,000.00 |
| Jun 30, 2020 | 13,000.00 |
| Jun 30, 2020 | 13,000.00 |
| Mar 31, 2020 | -2,000.00 |
| Mar 31, 2020 | -2,000.00 |